dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada GLP-1-RA inhibitors in the management of type 2 diabetes GLP-1 receptor agonist versus DPP-4

[Crossref] [PubMed] Ko MW, Chang SC, Ridha MA, et al

These results prove that GLP-1-based therapy may reduce inflammation and improve fatty liver disease in animal and human models

Probiotics and Type 1 Diabetes: An Interesting Connection A clinical trial on people with type 1 diabetes showed promising results using a probiotic blend ( Bifidobacterium longum , Lactobacillus bulgaricus , Streptococcus thermophilus ) over 12 weeks: Improved fasting blood sugar Reduced post-meal glucose spikes Better overnight stability And this was all without changing their insulin dose, suggesting that the gut flora itself helped balance blood sugar

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial